Results 81 to 90 of about 43,529 (272)
Tumor-induced osteomalacia: Easing the diagnosis with fibroblast growth factor 23
APIK Journal of Internal Medicine, 2022 Tumor-induced osteomalacia (TIO), is a rare paraneoplastic syndrome resulting in bone pain, muscle weakness, and recurrent fractures. Hypophosphatemia, hyperphosphaturia, low 1, 25 dihydroxyVitamin D, and normal serum calcium are noted.
Mala Dharmalingam, Lohit Kumbar
doaj +1 more source
Bone Reports, 2017 Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome clinically characterized by bone pain, fractures and muscle weakness. It is caused by tumoral overproduction of fibroblast growth factor 23 (FGF23) that acts primarily at the proximal ...
P. Florenzano, R. Gafni, M. Collins
semanticscholar +1 more source
Systemic Control of Bone Homeostasis by FGF23 Signaling [PDF]
, 2016 The regulation of phosphate metabolism as an influence on bone homeostasis is profound. Recent advances in understanding the systemic control of Fibroblast growth factor-23 (FGF23) has uncovered novel effectors of endocrine feedback loops for calcium ...
Clinkenbeard, Erica L. +1 more
core +1 more source
Kazan medical journal, 2021 Osteomalacia, being a rare disease in Russia in general (according to Skrobansky, 49 cases before 1908), occurs quite often in the area of the former. Kazan province and, moreover, almost exclusively among the Tatars.
openaire +1 more source
Journal of Parenteral and Enteral Nutrition, Volume 50, Issue 3, Page 339-351, April 2026.Abstract Ileostomy creation is common among patients with colorectal cancer, diverticulitis, and inflammatory bowel disease. Surgical removal or diversion of the colon can result in nutrition complications, most notably dehydration—a leading cause of hospital readmission—and increased risk of kidney injury.
Austin J. Hoeg +9 more
wiley +1 more source
BU Medical Center press release [PDF]
, 1990 Press release from the Boston University Medical ...
Boston University Medical Center, Office of Media Relations
core
Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 945-954, April 2026.Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak +2 more
wiley +1 more source
Osteomalacia: desde la sospecha clínica al tratamiento. Revisión del tema
Revista Colombiana de Endocrinología, Diabetes y Metabolismo, 2019 El propósito de este artículo es presentar una revisión de la literatura acerca de la epidemiología, fisiopatología, manifestaciones clínicas y manejo de la osteomalacia.
V. Duque +5 more
doaj +1 more source
Hearing loss and fluctuating hearing levels in X-linked hypophosphataemic osteomalacia [PDF]
, 2017 Background and objective: X-linked hypophosphataemic osteomalacia is the most common of the genetically determined forms of osteomalacia. The occurrence of hearing loss in X-linked hypophosphataemic osteomalacia has been known since 1984.
Gürtler, N. +3 more
core
Proceedings of the Rank Forum on Vitamin D [PDF]
, 2010 The Rank Forum on Vitamin D was held on 2nd and 3rd July 2009 at the University of Surrey, Guildford, UK. The workshop consisted of a series of scene-setting presentations to address the current issues and challenges concerning vitamin D and health, and ...
A. L. Darling +32 more
core +2 more sources